Eiger BioPharmaceuticals, AnGes get Zokinvy marketing approval in Japan

Eiger BioPharmaceuticals “announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy, or lonafarnib., a treatment for Hutchinson-Gilford progeria syndrome, HGPS, and processing deficient progeroid laminopathy (PDPL). The approval was based on the positive results of two pivotal clinical trials demonstrating that Zokinvy, an oral disease-modifying agent which targets the cause of progeria, lowered the risk of death in children by 72% and extended life by an average of 4.3 years in children and young adults with HGPS.”